Key Insights

Highlights

Success Rate

81% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 59/100

Termination Rate

16.7%

3 terminated out of 18 trials

Success Rate

81.3%

-5.3% vs benchmark

Late-Stage Pipeline

6%

1 trials in Phase 3/4

Results Transparency

46%

6 of 13 completed with results

Key Signals

6 with results81% success

Data Visualizations

Phase Distribution

16Total
Not Applicable (2)
P 1 (10)
P 2 (3)
P 3 (1)

Trial Status

Completed13
Terminated3
Withdrawn1
Active Not Recruiting1

Trial Success Rate

81.3%

Benchmark: 86.5%

Based on 13 completed trials

Clinical Trials (18)

Showing 18 of 18 trials
NCT05358249Phase 1Active Not Recruiting

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

NCT04166383Phase 2Terminated

VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)

NCT03377361Phase 1Completed

An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread

NCT03428958Phase 1Completed

A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment

NCT01291420Phase 1Completed

Dendritic Cell Vaccination for Patients with Solid Tumors

NCT05136092Not ApplicableCompletedPrimary

A Pilot Study to Determine Fructose Uptake by Primary Human Colorectal Tumors

NCT01545141Phase 1Terminated

Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer

NCT05484687Not ApplicableCompletedPrimary

Effect of Intravenous Infusion of Lidocaine on Patients Undergoing Radical Resection of Colorectal Tumors

NCT03050814Phase 2TerminatedPrimary

Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004

NCT02347735Completed

Predictive Factors for Anastomotic Leakage After Colorectal Surgery

NCT01139138Phase 1Completed

Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer

NCT01671592Phase 1Completed

Safety of Labeled Dendritic Cell (DC) Vaccines and Feasibility of Tracking by Magnetic Resonance Imaging (MRI)

NCT01675128Phase 1Completed

ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer

NCT01157039Phase 2Withdrawn

A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin

NCT01793207Completed

Peripheral Blood DNA Methylation Markers for the Early Detection of Colorectal Carcinoma in the Egyptian Population

NCT02399059Phase 3CompletedPrimary

Effect of Peritoneal Lavage With Clindamycin-Gentamicin Solution & Oncologic Outcome

NCT00704600Phase 1Completed

Nelfinavir, a Phase I/Phase II Rectal Cancer Study

NCT00478634Phase 1Completed

A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

Showing all 18 trials

Research Network

Activity Timeline